Vir Biotechnology’s Second Act Comes With a Mask

After COVID antibodies and a failed flu trial, Vir is betting on hepatitis delta and cancer drugs designed to switch on inside tumors. Its comeback has partners and cash. The decisive clinical tests are still ahead.